Carfilzomib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Carfilzomib" in English language version.

refsWebsite

Global rank English rank

14nih.gov

4^th place

8doi.org

2^nd place

3web.archive.org

1^st place

3myelomabeacon.com

low place

3fda.gov

447^th place

338^th place

2onclive.com

low place

2confex.com

6,094^th place

4,186^th place

1tga.gov.au

3,984^th place

2,622^nd place

1canada.ca

1,712^th place

1,063^rd place

1cancer.gov

1,684^th place

1,350^th place

1harvard.edu

18^th place

17^th place

1acs.org

1,248^th place

1,104^th place

1bizjournals.com

407^th place

241^st place

1asco.org

low place

1semanticscholar.org

11^th place

8^th place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1ascopost.com

low place

acs.org

cen.acs.org

"Carfilzomib: From Discovery To Drug". Chemical & Engineering News. 2012-08-27. Retrieved 2013-07-30.

asco.org

"PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis". ASCO 2011; Abstract 8027. 2011. Archived from the original on 2012-03-23. Retrieved 2011-09-01.

ascopost.com

Stenger, Matthew (January 31, 2018). "ASPIRE Trial: Final Overall Survival Results in Relapsed or Refractory Multiple Myeloma". The ASCO Post. Retrieved March 28, 2021.

bizjournals.com

"Onyx multiple myeloma drug wins FDA fast-track status". San Francisco Business Times. 2011-01-31. Retrieved 2011-09-01.

canada.ca

"Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.

cancer.gov

"NCI Drug Dictionary". National Cancer Institute. Retrieved 13 November 2020.

clinicaltrials.gov

"Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Versus Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma". ClinicalTrials.gov. 2011-08-04. Retrieved 2011-09-01.

confex.com

ash.confex.com

"Nikoletta Lendval, MD PhD et al. Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma". Presented at: 54th ASH Annual Meeting and Exposition: December 2012. Retrieved 2013-07-23.
"Final Results of a Frontline Phase 1/2 Study of Carfilzomib Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)". ASH 20111; Abstract 631. Retrieved 2012-02-27.

doi.org

Park JE, Park J, Jun Y, Oh Y, Ryoo G, Jeong YS, et al. (May 2019). "Expanding therapeutic utility of carfilzomib for breast cancer therapy by novel albumin-coated nanocrystal formulation". Journal of Controlled Release. 302: 148–159. doi:10.1016/j.jconrel.2019.04.006. PMC 6638563. PMID 30954620.
Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM (August 1999). "Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity". Proceedings of the National Academy of Sciences of the United States of America. 96 (18): 10403–8. Bibcode:1999PNAS...9610403M. doi:10.1073/pnas.96.18.10403. PMC 17900. PMID 10468620.
Myung J, Kim KB, Lindsten K, Dantuma NP, Crews CM (February 2001). "Lack of proteasome active site allostery as revealed by subunit-specific inhibitors". Molecular Cell. 7 (2): 411–20. doi:10.1016/S1097-2765(01)00188-5. PMID 11239469.
Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, et al. (September 2012). "An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib". British Journal of Haematology. 158 (6): 739–48. doi:10.1111/j.1365-2141.2012.09232.x. PMC 5818209. PMID 22845873.
Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, et al. (June 2012). "An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma". Blood. 119 (24): 5661–70. doi:10.1182/blood-2012-03-414359. PMC 4123327. PMID 22555973.
Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, et al. (August 2013). "Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety". Leukemia. 27 (8): 1707–14. doi:10.1038/leu.2013.29. PMC 3740399. PMID 23364621.
Guerrero-Garcia TA, Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Mitsiades C, et al. (December 2018). "The power of proteasome inhibition in multiple myeloma". Expert Review of Proteomics. 15 (12): 1033–1052. doi:10.1080/14789450.2018.1543595. PMID 30427223. S2CID 53303519.
Efentakis P, Kremastiotis G, Varela A, Nikolaou PE, Papanagnou ED, Davos CH, et al. (February 2019). "Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin". Blood. 133 (7): 710–723. doi:10.1182/blood-2018-06-858415. PMID 30482794.

fda.gov

"FDA Approves Kyprolis for Some Patients with Multiple Myeloma". FDA. 2012-07-20. Archived from the original on 2013-01-28. Retrieved 2013-07-23.
"Fast Track, Accelerated Approval and Priority Review; Accelerating Availability of New Drugs for Patients with Serious Diseases". FDA. Archived from the original on 2012-02-17. Retrieved 2012-02-27.

accessdata.fda.gov

"Drug Approval Package: Kyprolis (carfilzomib) for Injection NDA #202714". U.S. Food and Drug Administration (FDA). 20 August 2012. Retrieved 10 April 2023.

harvard.edu

ui.adsabs.harvard.edu

Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM (August 1999). "Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity". Proceedings of the National Academy of Sciences of the United States of America. 96 (18): 10403–8. Bibcode:1999PNAS...9610403M. doi:10.1073/pnas.96.18.10403. PMC 17900. PMID 10468620.

myelomabeacon.com

"Beacon Breaking News – Carfilzomib to Get Standard, Not Priority, FDA Review". The Myeloma Beacon. Retrieved 2012-02-27.
"European Hematology Association (EHA) 18th Congress. June 13-16, 2013". The Myeloma Beacon. 2013. Retrieved 2013-07-13.
"FDA Approves Kyprolis (Carfilzomib) For Relapsed And Refractory Multiple Myeloma". The Myeloma Beacon. Retrieved 2012-07-20.

nih.gov

onclive.com

Broderick JM (18 January 2018). "FDA Approves Carfilzomib Label Update in Myeloma". OncLive. Retrieved 10 April 2023.
Siegel DS, Martin T, Wang M, et al. (2011-03-09). "Results of PX-171- 003-A1, an open-label, single-arm, phase 2 study of carfilzomib in patients with relapsed and refractory multiple myeloma. Presented at: 52nd ASH Annual Meeting and Exposition; December 4-7, 2010; Orlando, Florida". December 2010. OncLive.com. Retrieved 2011-09-01.

semanticscholar.org

api.semanticscholar.org

Guerrero-Garcia TA, Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Mitsiades C, et al. (December 2018). "The power of proteasome inhibition in multiple myeloma". Expert Review of Proteomics. 15 (12): 1033–1052. doi:10.1080/14789450.2018.1543595. PMID 30427223. S2CID 53303519.

tga.gov.au

"Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

web.archive.org

"FDA Approves Kyprolis for Some Patients with Multiple Myeloma". FDA. 2012-07-20. Archived from the original on 2013-01-28. Retrieved 2013-07-23.
"Fast Track, Accelerated Approval and Priority Review; Accelerating Availability of New Drugs for Patients with Serious Diseases". FDA. Archived from the original on 2012-02-17. Retrieved 2012-02-27.
"PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis". ASCO 2011; Abstract 8027. 2011. Archived from the original on 2012-03-23. Retrieved 2011-09-01.

Carfilzomib (English Wikipedia)

acs.org

cen.acs.org

asco.org

ascopost.com

bizjournals.com

canada.ca

cancer.gov

clinicaltrials.gov

confex.com

ash.confex.com

doi.org

fda.gov

fda.gov

accessdata.fda.gov

harvard.edu

ui.adsabs.harvard.edu

myelomabeacon.com

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

onclive.com

semanticscholar.org

api.semanticscholar.org

tga.gov.au

web.archive.org